🇺🇸 Rituximab Biosimilar in United States
23 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 23
Most-reported reactions
- Off Label Use — 4 reports (17.39%)
- Septic Shock — 3 reports (13.04%)
- Alanine Aminotransferase Increased — 2 reports (8.7%)
- Decreased Appetite — 2 reports (8.7%)
- Dyspnoea — 2 reports (8.7%)
- Hypokalaemia — 2 reports (8.7%)
- Neoplasm — 2 reports (8.7%)
- Neuropathy Peripheral — 2 reports (8.7%)
- Neutropenia — 2 reports (8.7%)
- Sepsis — 2 reports (8.7%)
Rituximab Biosimilar in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Rituximab Biosimilar approved in United States?
Rituximab Biosimilar does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rituximab Biosimilar in United States?
Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.